Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

TRPV1 activation power can switch an action mode for its polypeptide ligands.

Nikolaev MV, Dorofeeva NA, Komarova MS, Korolkova YV, Andreev YA, Mosharova IV, Grishin EV, Tikhonov DB, Kozlov SA.

PLoS One. 2017 May 5;12(5):e0177077. doi: 10.1371/journal.pone.0177077. eCollection 2017.

2.

Modulation of TRPV1-dependent contractility of normal and diabetic bladder smooth muscle by analgesic toxins from sea anemone Heteractis crispa.

Philyppov IB, Paduraru ON, Andreev YA, Grishin EV, Shuba YM.

Life Sci. 2012 Nov 2;91(19-20):912-20. doi: 10.1016/j.lfs.2012.09.001. Epub 2012 Sep 12.

PMID:
22982418
3.

Analgesic compound from sea anemone Heteractis crispa is the first polypeptide inhibitor of vanilloid receptor 1 (TRPV1).

Andreev YA, Kozlov SA, Koshelev SG, Ivanova EA, Monastyrnaya MM, Kozlovskaya EP, Grishin EV.

J Biol Chem. 2008 Aug 29;283(35):23914-21. doi: 10.1074/jbc.M800776200. Epub 2008 Jun 25.

4.

Kunitz-Type Peptide HCRG21 from the Sea Anemone Heteractis crispa Is a Full Antagonist of the TRPV1 Receptor.

Monastyrnaya M, Peigneur S, Zelepuga E, Sintsova O, Gladkikh I, Leychenko E, Isaeva M, Tytgat J, Kozlovskaya E.

Mar Drugs. 2016 Dec 15;14(12). pii: E229.

5.

Polypeptide modulators of TRPV1 produce analgesia without hyperthermia.

Andreev YA, Kozlov SA, Korolkova YV, Dyachenko IA, Bondarenko DA, Skobtsov DI, Murashev AN, Kotova PD, Rogachevskaja OA, Kabanova NV, Kolesnikov SS, Grishin EV.

Mar Drugs. 2013 Dec 16;11(12):5100-15. doi: 10.3390/md11125100.

6.

[New polypeptide components from the Heteractis crispa sea anemone with analgesic activity].

Kozlov SA, Andreev IaA, Murashev AN, Skobtsov DI, D'iachenko IA, Grishin EV.

Bioorg Khim. 2009 Nov-Dec;35(6):789-98. Russian.

PMID:
20208578
7.

[Interaction of sea amemone Heteractis crispa Kunitz type polypeptides with pain vanilloid receptor TRPV1: in silico investigation].

Zelepuga EA, Tabakmakher VM, Chausova VE, monastyrnaia MM, Isaeva MP, Kozlovskaia ÉP.

Bioorg Khim. 2012 Mar-Apr;38(2):185-98. Russian.

PMID:
22792722
8.

Phenylarsine oxide as a redox modulator of transient receptor potential vanilloid type 1 channel function.

Carlin KP, Wu G, Patel A, Crumley G, Ilyin VI.

J Neurosci Res. 2015 Feb;93(2):309-20. doi: 10.1002/jnr.23479. Epub 2014 Sep 24.

PMID:
25250537
9.

Acidification of rat TRPV1 alters the kinetics of capsaicin responses.

Neelands TR, Jarvis MF, Han P, Faltynek CR, Surowy CS.

Mol Pain. 2005 Sep 28;1:28.

10.

Structure-activity relationships of vanilloid receptor agonists for arteriolar TRPV1.

Czikora Á, Lizanecz E, Bakó P, Rutkai I, Ruzsnavszky F, Magyar J, Pórszász R, Kark T, Facskó A, Papp Z, Édes I, Tóth A.

Br J Pharmacol. 2012 Mar;165(6):1801-1812. doi: 10.1111/j.1476-5381.2011.01645.x.

11.

Biological activity of a polypeptide modulator of TRPV1 receptor.

Dyachenko IA, Andreev YA, Logashina YA, Murashev AN, Grishin EV.

Dokl Biol Sci. 2015 Nov;465(1):279-81. doi: 10.1134/S0012496615060034. Epub 2016 Jan 5.

PMID:
26725234
12.

Structural insights into transient receptor potential vanilloid type 1 (TRPV1) from homology modeling, flexible docking, and mutational studies.

Lee JH, Lee Y, Ryu H, Kang DW, Lee J, Lazar J, Pearce LV, Pavlyukovets VA, Blumberg PM, Choi S.

J Comput Aided Mol Des. 2011 Apr;25(4):317-27. doi: 10.1007/s10822-011-9421-5. Epub 2011 Mar 30.

13.

The pain receptor TRPV1 displays agonist-dependent activation stoichiometry.

Hazan A, Kumar R, Matzner H, Priel A.

Sci Rep. 2015 Jul 21;5:12278. doi: 10.1038/srep12278.

14.

Functional transient receptor potential vanilloid 1 and transient receptor potential vanilloid 4 channels along different segments of the renal vasculature.

Chen L, Kaßmann M, Sendeski M, Tsvetkov D, Marko L, Michalick L, Riehle M, Liedtke WB, Kuebler WM, Harteneck C, Tepel M, Patzak A, Gollasch M.

Acta Physiol (Oxf). 2015 Feb;213(2):481-91. doi: 10.1111/apha.12355. Epub 2014 Aug 21.

PMID:
25069877
15.
16.

A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation.

Klionsky L, Tamir R, Holzinger B, Bi X, Talvenheimo J, Kim H, Martin F, Louis JC, Treanor JJ, Gavva NR.

J Pharmacol Exp Ther. 2006 Oct;319(1):192-8. Epub 2006 Jul 14.

PMID:
16844842
17.

Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1.

Lizanecz E, Bagi Z, Pásztor ET, Papp Z, Edes I, Kedei N, Blumberg PM, Tóth A.

Mol Pharmacol. 2006 Mar;69(3):1015-23. Epub 2005 Dec 7.

PMID:
16338989
18.

Presynaptic inhibition of transient receptor potential vanilloid type 1 (TRPV1) receptors by noradrenaline in nociceptive neurons.

Chakraborty S, Elvezio V, Kaczocha M, Rebecchi M, Puopolo M.

J Physiol. 2017 Apr 15;595(8):2639-2660. doi: 10.1113/JP273455. Epub 2017 Feb 22.

19.

Molecular determinants of vanilloid sensitivity in TRPV1.

Gavva NR, Klionsky L, Qu Y, Shi L, Tamir R, Edenson S, Zhang TJ, Viswanadhan VN, Toth A, Pearce LV, Vanderah TW, Porreca F, Blumberg PM, Lile J, Sun Y, Wild K, Louis JC, Treanor JJ.

J Biol Chem. 2004 May 7;279(19):20283-95. Epub 2004 Mar 2.

20.

Evodiamine functions as an agonist for the vanilloid receptor TRPV1.

Pearce LV, Petukhov PA, Szabo T, Kedei N, Bizik F, Kozikowski AP, Blumberg PM.

Org Biomol Chem. 2004 Aug 21;2(16):2281-6. Epub 2004 Jul 27.

PMID:
15305207

Supplemental Content

Support Center